{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-251268","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.907685+00:00","generated_at":"2026-05-30T05:27:40.870952+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cytek Q3 revenue $51.5M (+7% YoY); net income $0.9M vs loss year ago","bullets":["Total revenue $51.5M, up 7% vs Q3 2023; year-to-date revenue $143.0M, up 6%.","GAAP net income $0.9M vs net loss of $6.5M in Q3 2023; adjusted EBITDA $7.6M vs $3.7M.","Installed base expanded to 2,821 units, adding 164 units in Q3.","Repurchased $12.1M of stock during Q3; cash and securities $277.8M.","FY2024 revenue guidance reaffirmed at $203-210M, expecting positive operating cash flow."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-251268","json":"https://secwatch.observer/filing/0001193125-24-251268.json","markdown":"https://secwatch.observer/filing/0001193125-24-251268.md","text":"https://secwatch.observer/filing/0001193125-24-251268.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312524251268/0001193125-24-251268-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312524251268/d825275d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:27:40.870952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}